Immune signatures predict prognosis in localized cancer

David S. Hsu, Mickey K. Kim, Bala S. Balakumaran, Chaitanya R. Acharya, Carey K. Anders, Tim Clay, H. Kim Lyerly, Charles G. Drake, Michael A. Morse, Phillip G. Febbo

Research output: Contribution to journalArticle

Abstract

The host immune response can impact cancer growth, prognosis, and response to therapy. In colorectal cancer, the presence of cells involved with T-cell-mediated adaptive immunity predicts survival better than the current staging method. We used the expression of genes recently associated with host immune responses (TH1-mediated adaptive immunity, inflammation, and immune suppression) to perform hierarchical clustering of multiple large cohorts of cancer specimens to determine if immune-related gene expression resulted in clinical significant groupings of tumors. Microarray data from prostate cancer (n 79), breast cancer (n 132), lung cancer (n 84), glioblastoma multiforme (n 120), and lymphoma (n 127) were analyzed. Among adenocarcinomas, the TH1-mediated adaptive immunity genes were consistently associated with better prognosis, while genes associated with inflammation and immune suppression were variably associated with outcome. Specifically, increased expression of the TH1-mediated adaptive immunity genes was associated with good prognosis in breast cancer patients under 45 years of age (p .04, hazard ratio [HR] 0.42) and in prostate cancer patients (p .03, HR 0.36) but not in lung cancer patients (p 0.45, HR 1.37). In lymphoma, patients with increased expression of inflammation and immune suppression genes had better prognosis than those expressing the TH1-mediated adaptive immunity genes (p .01, HR 0.43) and in glioblastoma multiforme, the expression of inflammation genes conferred improved prognosis than those expressing immune suppression genes (p 0.05, HR 0.62). In aggregate, the gene expression signatures implicating specific components of the immune response hold prognostic import across solid tumors.

Original languageEnglish (US)
Pages (from-to)765-773
Number of pages9
JournalCancer Investigation
Volume28
Issue number7
DOIs
StatePublished - Jul 2010

Fingerprint

Adaptive Immunity
Genes
Inflammation
Neoplasms
Glioblastoma
Gene Expression
Lymphoma
Lung Neoplasms
Prostatic Neoplasms
Breast Neoplasms
Transcriptome
Cellular Immunity
Cluster Analysis
Colorectal Neoplasms
Adenocarcinoma
T-Lymphocytes
Survival
Growth

Keywords

  • Cancer
  • Gene expression
  • Immunology

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Hsu, D. S., Kim, M. K., Balakumaran, B. S., Acharya, C. R., Anders, C. K., Clay, T., ... Febbo, P. G. (2010). Immune signatures predict prognosis in localized cancer. Cancer Investigation, 28(7), 765-773. https://doi.org/10.3109/07357900903095755

Immune signatures predict prognosis in localized cancer. / Hsu, David S.; Kim, Mickey K.; Balakumaran, Bala S.; Acharya, Chaitanya R.; Anders, Carey K.; Clay, Tim; Lyerly, H. Kim; Drake, Charles G.; Morse, Michael A.; Febbo, Phillip G.

In: Cancer Investigation, Vol. 28, No. 7, 07.2010, p. 765-773.

Research output: Contribution to journalArticle

Hsu, DS, Kim, MK, Balakumaran, BS, Acharya, CR, Anders, CK, Clay, T, Lyerly, HK, Drake, CG, Morse, MA & Febbo, PG 2010, 'Immune signatures predict prognosis in localized cancer', Cancer Investigation, vol. 28, no. 7, pp. 765-773. https://doi.org/10.3109/07357900903095755
Hsu DS, Kim MK, Balakumaran BS, Acharya CR, Anders CK, Clay T et al. Immune signatures predict prognosis in localized cancer. Cancer Investigation. 2010 Jul;28(7):765-773. https://doi.org/10.3109/07357900903095755
Hsu, David S. ; Kim, Mickey K. ; Balakumaran, Bala S. ; Acharya, Chaitanya R. ; Anders, Carey K. ; Clay, Tim ; Lyerly, H. Kim ; Drake, Charles G. ; Morse, Michael A. ; Febbo, Phillip G. / Immune signatures predict prognosis in localized cancer. In: Cancer Investigation. 2010 ; Vol. 28, No. 7. pp. 765-773.
@article{2e7ffc76a2c14559ad9220760d05259b,
title = "Immune signatures predict prognosis in localized cancer",
abstract = "The host immune response can impact cancer growth, prognosis, and response to therapy. In colorectal cancer, the presence of cells involved with T-cell-mediated adaptive immunity predicts survival better than the current staging method. We used the expression of genes recently associated with host immune responses (TH1-mediated adaptive immunity, inflammation, and immune suppression) to perform hierarchical clustering of multiple large cohorts of cancer specimens to determine if immune-related gene expression resulted in clinical significant groupings of tumors. Microarray data from prostate cancer (n 79), breast cancer (n 132), lung cancer (n 84), glioblastoma multiforme (n 120), and lymphoma (n 127) were analyzed. Among adenocarcinomas, the TH1-mediated adaptive immunity genes were consistently associated with better prognosis, while genes associated with inflammation and immune suppression were variably associated with outcome. Specifically, increased expression of the TH1-mediated adaptive immunity genes was associated with good prognosis in breast cancer patients under 45 years of age (p .04, hazard ratio [HR] 0.42) and in prostate cancer patients (p .03, HR 0.36) but not in lung cancer patients (p 0.45, HR 1.37). In lymphoma, patients with increased expression of inflammation and immune suppression genes had better prognosis than those expressing the TH1-mediated adaptive immunity genes (p .01, HR 0.43) and in glioblastoma multiforme, the expression of inflammation genes conferred improved prognosis than those expressing immune suppression genes (p 0.05, HR 0.62). In aggregate, the gene expression signatures implicating specific components of the immune response hold prognostic import across solid tumors.",
keywords = "Cancer, Gene expression, Immunology",
author = "Hsu, {David S.} and Kim, {Mickey K.} and Balakumaran, {Bala S.} and Acharya, {Chaitanya R.} and Anders, {Carey K.} and Tim Clay and Lyerly, {H. Kim} and Drake, {Charles G.} and Morse, {Michael A.} and Febbo, {Phillip G.}",
year = "2010",
month = "7",
doi = "10.3109/07357900903095755",
language = "English (US)",
volume = "28",
pages = "765--773",
journal = "Cancer Investigation",
issn = "0735-7907",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - Immune signatures predict prognosis in localized cancer

AU - Hsu, David S.

AU - Kim, Mickey K.

AU - Balakumaran, Bala S.

AU - Acharya, Chaitanya R.

AU - Anders, Carey K.

AU - Clay, Tim

AU - Lyerly, H. Kim

AU - Drake, Charles G.

AU - Morse, Michael A.

AU - Febbo, Phillip G.

PY - 2010/7

Y1 - 2010/7

N2 - The host immune response can impact cancer growth, prognosis, and response to therapy. In colorectal cancer, the presence of cells involved with T-cell-mediated adaptive immunity predicts survival better than the current staging method. We used the expression of genes recently associated with host immune responses (TH1-mediated adaptive immunity, inflammation, and immune suppression) to perform hierarchical clustering of multiple large cohorts of cancer specimens to determine if immune-related gene expression resulted in clinical significant groupings of tumors. Microarray data from prostate cancer (n 79), breast cancer (n 132), lung cancer (n 84), glioblastoma multiforme (n 120), and lymphoma (n 127) were analyzed. Among adenocarcinomas, the TH1-mediated adaptive immunity genes were consistently associated with better prognosis, while genes associated with inflammation and immune suppression were variably associated with outcome. Specifically, increased expression of the TH1-mediated adaptive immunity genes was associated with good prognosis in breast cancer patients under 45 years of age (p .04, hazard ratio [HR] 0.42) and in prostate cancer patients (p .03, HR 0.36) but not in lung cancer patients (p 0.45, HR 1.37). In lymphoma, patients with increased expression of inflammation and immune suppression genes had better prognosis than those expressing the TH1-mediated adaptive immunity genes (p .01, HR 0.43) and in glioblastoma multiforme, the expression of inflammation genes conferred improved prognosis than those expressing immune suppression genes (p 0.05, HR 0.62). In aggregate, the gene expression signatures implicating specific components of the immune response hold prognostic import across solid tumors.

AB - The host immune response can impact cancer growth, prognosis, and response to therapy. In colorectal cancer, the presence of cells involved with T-cell-mediated adaptive immunity predicts survival better than the current staging method. We used the expression of genes recently associated with host immune responses (TH1-mediated adaptive immunity, inflammation, and immune suppression) to perform hierarchical clustering of multiple large cohorts of cancer specimens to determine if immune-related gene expression resulted in clinical significant groupings of tumors. Microarray data from prostate cancer (n 79), breast cancer (n 132), lung cancer (n 84), glioblastoma multiforme (n 120), and lymphoma (n 127) were analyzed. Among adenocarcinomas, the TH1-mediated adaptive immunity genes were consistently associated with better prognosis, while genes associated with inflammation and immune suppression were variably associated with outcome. Specifically, increased expression of the TH1-mediated adaptive immunity genes was associated with good prognosis in breast cancer patients under 45 years of age (p .04, hazard ratio [HR] 0.42) and in prostate cancer patients (p .03, HR 0.36) but not in lung cancer patients (p 0.45, HR 1.37). In lymphoma, patients with increased expression of inflammation and immune suppression genes had better prognosis than those expressing the TH1-mediated adaptive immunity genes (p .01, HR 0.43) and in glioblastoma multiforme, the expression of inflammation genes conferred improved prognosis than those expressing immune suppression genes (p 0.05, HR 0.62). In aggregate, the gene expression signatures implicating specific components of the immune response hold prognostic import across solid tumors.

KW - Cancer

KW - Gene expression

KW - Immunology

UR - http://www.scopus.com/inward/record.url?scp=77954801902&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954801902&partnerID=8YFLogxK

U2 - 10.3109/07357900903095755

DO - 10.3109/07357900903095755

M3 - Article

C2 - 20569070

AN - SCOPUS:77954801902

VL - 28

SP - 765

EP - 773

JO - Cancer Investigation

JF - Cancer Investigation

SN - 0735-7907

IS - 7

ER -